Literature DB >> 835592

Therapy of the idiopathic nephrotic syndrome with alternate day steroids.

W K Bolton, N O Atuk, B C Sturgill, F B Westervelt.   

Abstract

Eighty-one adult patients with the idiopathic nephrotic syndrome were treated with prednisone, 60 to 120 mg, on alternate days. Treatment was continued with diminishing drug doses for up to 10 years. Biopsy specimens were categorized as showing lipoid nephrosis 36 per cent, focal sclerosis 12 per cent, diffuse proliferative 22 per cent and membranous nephropathy 30 per cent. Patients with systemic causes of the nephrotic syndrome were excluded. Proteinuria decreased to normal or to less than or equal to 3 g with a greater than or equal to 50 per cent decrease from base line in 83 per cent of the patients with lipoid nephrosis, 30 per cent of the patients with focal sclerosis, 50 per cent of the patients with diffuse proliferative nephritis and 71 per cent of the patients with membranous nephropathy. Improvement occurred in those with focal sclerosis, diffuse proliferative nephritis and membranous nephropathy only after prolonged treatment (14 to 15 months). Stable or improved renal function occurred in 97 per cent of those with lipoid nephrosis, 50 per cent of those with focal sclerosis, 73 per cent of those with diffuse proliferative nephritis and in 83 per cent of those with membranous nephropathy. Death or dialysis occurred in 12 per cent of the patients, and complications coincident with treatment occurred once every 12 patient years. Compared to other series of patients with the idiopathic nephrotic syndrome, therapy of our patients with prolonged alternate day steroids resulted in (1) decreased protein excretion, (2) maintenance of good renal function and (3) decreased number of complications of therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 835592     DOI: 10.1016/0002-9343(77)90350-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

Review 1.  Medical decision-making in membranous nephropathy: how to use limited clinical research evidence in patient management.

Authors:  Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

2.  Long-term effects of steroid and cytostatic treatment on the clinical course of idiopathic membranous glomerulonephritis (retrospective study).

Authors:  G Mohácsi; A Magori; S Sonkodi
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

Review 3.  Therapy of idiopathic membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; P Passerini
Journal:  Springer Semin Immunopathol       Date:  1987

4.  Targeted enzyme therapy of experimental glomerulonephritis in rats.

Authors:  R B White; L Lowrie; J E Stork; S S Iskandar; M E Lamm; S N Emancipator
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Membranous nephropathy: high-dose alternate-day therapy with prednisone.

Authors:  J Hopper; C G Biava; W H Tu
Journal:  West J Med       Date:  1981-07

6.  Glomerular lesions in adolescents with gross hematuria or the nephrotic syndrome. Report of the Southwest Pediatric Nephrology Study Group.

Authors:  R J Hogg; F G Silva; P L Berry; J E Wenz
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

7.  Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis.

Authors:  R Brunkhorst; E Wrenger; K M Koch
Journal:  Clin Investig       Date:  1994-03

8.  Adult minimal change nephropathy: experience of the collaborative study of glomerular disease.

Authors:  C H Coggins
Journal:  Trans Am Clin Climatol Assoc       Date:  1986

9.  Later Response to Corticosteroids in Adults With Primary Focal Segmental Glomerular Sclerosis Is Associated With Favorable Outcomes.

Authors:  Ilse M Rood; Aernoud Bavinck; Beata S Lipska-Ziętkiewicz; Dorien Lugtenberg; Franz Schaefer; Jeroen K J Deegens; Jack F M Wetzels
Journal:  Kidney Int Rep       Date:  2021-10-29

Review 10.  Immunosuppressive treatment for focal segmental glomerulosclerosis in adults.

Authors:  Norbert Braun; Frank Schmutzler; Catalina Lange; Annalisa Perna; Giuseppe Remuzzi; Teut Risler; Narelle S Willis
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.